Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Xenetic Biosciences, Inc.

NASDAQ: XBIO · Life Sciences · 4 alerts · CIK 1534525

Share price
$1.49Close, Nov 16
Market cap
$3.49M
Shares outstanding
2.34MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Xenetic Biosciences, Inc. filings on SEC EDGAR ↗

8:36 AM ET 8-K
M&A Deal

Xenetic Biosciences M&A Deal with Santersus AG

Xenetic Biosciences provided a status update on its pending all-stock acquisition of Santersus AG, which is expected to transform the company into a clinical-stage entity focused on targeting neutrophil extracellular traps (NETs). The combined company will feature a pipeline with four first-in-class programs, including pivotal-stage programs in sepsis and SLE that have received FDA Breakthrough Device Designation.

Counterparty
Santersus AG

“This is a defining period for Xenetic as we work toward completing a transaction that we believe has the potential to fundamentally transform the Company's clinical development profile and long-term value proposition.”

James Parslow, Interim Chief Executive Officer and Chief Financial Officer

“We believe the complementary nature of NucleoCapture® and Xenetic's DNase platform provides a differentiated opportunity to address NETs through distinct mechanisms, potentially expanding the therapeutic reach of the combined platform.”

James Parslow, Interim Chief Executive Officer and Chief Financial Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.